Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Pharmacology, Toxicology and Pharmaceutical Science
3
2%
Other
9
7%
Unknown
62
50%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2026.
All research outputs
#1,561,774
of 34,492,055 outputs
Outputs from Annals of the Rheumatic Diseases
#960
of 10,607 outputs
Outputs of similar age
#29,761
of 470,766 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#17
of 60 outputs
Altmetric has tracked 34,492,055 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,607 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 470,766 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
